NCT01396200View on ClinicalTrials.gov

Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Myeloma
Interventions
DRUG

Hydroxychloroquine

Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily

DRUG

Rapamycin

Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01396200 - Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine | Biotech Hunter | Biotech Hunter